Derudas Marco, Vanpouille Christophe, Carta Davide, Zicari Sonia, Andrei Graciela, Snoeck Robert, Brancale Andrea, Margolis Leonid, Balzarini Jan, McGuigan Christopher
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University , Cardiff, CF10 3NB, U.K.
Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, Maryland 20892, United States.
J Med Chem. 2017 Sep 28;60(18):7876-7896. doi: 10.1021/acs.jmedchem.7b01009. Epub 2017 Sep 19.
Following our findings on the anti-human immunodeficiency virus (HIV) activity of acyclovir (ACV) phosphate prodrugs, we herein report the ProTide approach applied to a series of acyclic nucleosides aimed at the identification of novel and selective antiviral, in particular anti-HIV agents. Acyclic nucleoside analogues used in this study were identified through a virtual screening using HIV-reverse transcriptase (RT), adenylate/guanylate kinase, and human DNA polymerase γ. A total of 39 new phosphate prodrugs were synthesized and evaluated against HIV-1 (in vitro and ex vivo human tonsillar tissue system) and human herpes viruses. Several ProTide compounds showed substantial potency against HIV-1 at low micromolar range while the parent nucleosides were not effective. Also, pronounced inhibition of herpesvirus replication was observed. A carboxypeptidase-mediated hydrolysis study was performed for a selection of compounds to assess the formation of putative metabolites and support the biological activity observed.
基于我们对阿昔洛韦(ACV)磷酸酯前药抗人类免疫缺陷病毒(HIV)活性的研究结果,我们在此报告将前药策略应用于一系列无环核苷,旨在鉴定新型选择性抗病毒药物,尤其是抗HIV药物。本研究中使用的无环核苷类似物是通过使用HIV逆转录酶(RT)、腺苷酸/鸟苷酸激酶和人类DNA聚合酶γ进行虚拟筛选来确定的。总共合成了39种新的磷酸酯前药,并针对HIV-1(体外和离体人扁桃体组织系统)和人类疱疹病毒进行了评估。几种前药化合物在低微摩尔范围内对HIV-1显示出显著的效力,而母体核苷则无效。此外,还观察到对疱疹病毒复制有明显抑制作用。对部分化合物进行了羧肽酶介导的水解研究,以评估假定代谢物的形成并支持所观察到的生物活性。